
    
      OUTLINE:

      Patients receive apalutamide orally (PO) once daily (QD) for 90 days in the absence of
      disease progression or unacceptable toxicity.

      After completion of the study treatment, patients are followed up at 180, 365, 545, and 730
      days; and at years 3, 4 and 5 by medical record review.
    
  